| Lecture Topic | Speaker | Affiliation | |
|---|---|---|---|
| Sesson 1 | Introduction to the Korean Dementia Association’s recommendation for the use of Lecanemab-1 | Seol-Heui Han | Konkuk University |
| Background of recommendation development and considerations for selecting appropriate patients treated by Lecanemab | Kee Hyung Park | Gachon University Gil Medical Center | |
| Test method to select patients suitable for lecanemab use | Seong-Ho Koh | Hanyang University Guri Hospital | |
| Preparation for use of lecanemab in clinical practice | Seong Hye Choi | Inha University Hospital | |
| Q & A | |||
| Sesson 2 | Introduction to the Korean Dementia Association’s recommendation for the use of Lecanemab-2 | Seung Hyun Kim | Hanyang University Hospital |
| Method of monitoring patients receiving lecanemab | Geon Ha Kim | Ewha Womans University Mokdong Hospital | |
| Realistic problems that can occur in actual outpatient settings | Dong Won Yang | The Catholic University of Korea Seoul St. Mary’s Hospital | |
| Considerations of other situations in which lecanemab may be useful | So Young Moon | Ajou University Hospital | |
| Q & A | |||
| Sesson 3 | ARIA | ||
| How to easily diagnose ARIA | Won-Jin Moon | Konkuk University | |
| Q & A | |||
| Sesson 4 | Experience in Japan | SangYun Kim | Seoul National University Bundang Hospital |
| Lecanemab in Japna: Current status and Experience of Japan; including policies and necessary facilities | Atsushi Iwata | Tokyo Metropolitan Institute for Geriatrics and Gerontology | |
| Q & A | |||
| Sesson 5 | General discussion | KunWoo Park | Korea University Anam Hospital |
| General discussion |
| Lecture Topic | Speaker | Affiliation | |
|---|---|---|---|
| Sesson 1 | Is the recently developed treatment for Alzheimer's disease worth using? | Seol-Heui Han | Konkuk University |
| 8:30~9:00 | Clinical effect of Lecanemab and Donanemab | Seong Hye Choi | Inha University Hospital |
| 9:00~9:20 | Is ARIA controllable side effect? | Hee-Jin Kim | Hanyang University Hospital |
| Sesson 2 | What is being done to ensure proper use of new AD treatments? | Dong Won Yang | The Catholic University of Korea Seoul St. Mary’s Hospital |
| 9:20~9:40 | Review of usage guidelines for Aducanumab and Lecanemab | Jae-Sung Lim | Asan Medical Center |
| 9:40~10:00 | America prepares for new AD treatments: ALZ-NET, Preparedness for Newly Approved DMT Drugs in US | Alzheimer's Association, US | Alzheimer's Association, US |
| 10:00~10:20 | Q & A | ||
| Sesson 3 | What should we prepare for domestic use of new treatments? | SangYun Kim | Seoul National University Bundang Hospital |
| 10:40~10:55 | What are the appropriate guidelines for domestic amyloid and tau PET? | Chan-Nyoung Lee | Korea University Anam Hospital |
| 10:55~11:10 | Is it impossible to replace imaging tests with cerebrospinal fluid tests in Korea? | Sun Ah Park | Ajou University Hospital |
| 11:10~11:25 | What level has blood-based testing reached? | Seong-Ho Koh | Hanyang University Guri Hospital |
| 11:25~11:40 | What are the expected changes to the healthcare system? | Hojin Choi | Hanyang University Guri Hospital |
| Sesson 4 | Panel discussion: Is early domestic approval of new drugs necessary? | Kee Hyung Park | Gachon University Gil Medical Center |
| 11:40~12:30 | Panel discussion: Senior Health Department, Ministry of Health and Welfare, Korea Dementia Association, Central Dementia Center, Pharmaceutical company |
||
Will be updated!
Will be updated!
Will be updated!
Will be updated!
Will be updated!
Will be updated!
Will be updated!
Will be updated!
Will be updated!
Will be updated!
Will be updated!
Will be updated!
Will be updated!
Will be updated!
Will be updated!
Will be updated!
Will be updated!
Will be updated!
Will be updated!
Will be updated!
Will be updated!
Will be updated!
Will be updated!
Will be updated!
Will be updated!